Chemokines and their receptors in oral squamous cell carcinoma: mechanisms, clinical significance, and therapeutic implications

Dandan Li, Shuangshuang Chen, Jiahao Ji, Zhenwu Wang, Han Zhou, Zebin Liao, Qun TangFrontiers in Immunology 2025 · DOI

Abstract: Chemokines, a category of cytokines exhibiting chemotactic properties, have been thoroughly investigated as targets in cancer treatment in recent decades. In oral squamous cell carcinoma (OSCC), a prevalent and high-risk malignancy of the head and neck, chemokines interact with their specific receptors to initiate downstream signaling pathways. This signaling influences not only tumor cell proliferation, migration, invasion, and metastasis of oral cancer cells but also angiogenesis and vascular maturation. Furthermore, they modulate the tumor microenvironment (TME), which consists of diverse cellular and molecular components that collectively create a permissive niche for tumor growth, metastasis, and therapeutic resistance. This modulation impacts the recruitment and functionality of immune cells, which in turn influences tumor immune evasion and immune surveillance. Various chemokines and their receptors have distinct expression patterns in oral cancer tissues compared to normal tissues. Certain chemokines may function as prospective diagnostic markers, prognostic indicators, and therapeutic targets. In this review, we systematically summarize research advancements on chemokines in OSCC, elucidating their molecular mechanisms in tumor initiation and progression with a focus on the dualistic roles of key chemokine families (e.g., CCL2/5/20/19/21, CXCL1/8/12, CX3CL1) in regulating immune responses, tumor-stroma interactions, vascular remodeling, and chemotherapy resistance. We also recap current chemokine/receptor-targeted therapeutic strategies and discuss the limitations of existing research, including incomplete mechanistic understanding of understudied chemokine subfamilies (beyond CXC and CC subfamilies) and limited clinical translation of chemokine-based diagnostics and therapeutics. Finally, we propose future research directions: prioritizing patient stratification based on chemokine profiles, developing targeted delivery systems for chemokine antagonists, and combining these approaches with emerging therapies to overcome treatment resistance. This review underscores the critical role of chemokines in OSCC biology and their promising potential to guide the development of novel, effective therapeutic interventions.

Introduction: The Role of Chemokines in OSCC

Oral Squamous Cell Carcinoma (OSCC) remains a significant global health burden, characterized by aggressive local invasion and a high propensity for lymph node metastasis. Despite advances in surgery and radiotherapy, five-year survival rates have stagnated. The core challenge lies in the Tumor Microenvironment (TME)—a complex ecosystem of immune cells, fibroblasts, and vascular components that the tumor "reprograms" to support its own growth.

Chemokines, small signaling proteins with chemotactic properties, act as master orchestrators within this environment. By interacting with specific receptors, they initiate downstream signaling pathways that drive tumor cell proliferation, migration, and metastasis, while also modulating the immune landscape to favor tumor survival over surveillance.

The Chemokine-Receptor Network in the Tumor Microenvironment

The TME in OSCC is a dynamic space where chemokines dictate the recruitment and functionality of various cell types. They are responsible for attracting "pro-tumor" immune cells, such as Regulatory T cells (Tregs) and Myeloid-Derived Suppressor Cells (MDSCs), which help the tumor evade the immune system.

Summary of key chemokines, their receptors, and functional roles in OSCC.

As detailed in the table above, different chemokine families (CC, CXC, CX3C) play specialized roles. For example, the CCL2/CCR2 and CXCL12/CXCR4 axes are critical for recruiting tumor-associated macrophages (TAMs) and promoting the formation of a "pre-metastatic niche" in lymph nodes. Interestingly, common oral pathogens like Fusobacterium nucleatum can trigger the dysregulation of these molecules, effectively helping the tumor "hide" from immune detection.

Molecular Mechanisms of Malignancy

Chemokines drive OSCC progression through several key molecular mechanisms:

  1. Signaling Activation: Binding to receptors triggers pathways like PI3K/AKT and MAPK, which are essential for cell survival and the Epithelial-Mesenchymal Transition (EMT), allowing cancer cells to become more mobile.
  2. Physical Landscape Remodeling: Chemokines induce the release of Matrix Metalloproteinases (MMPs), which degrade the extracellular matrix, "clearing a path" for cancer cells to invade surrounding tissues.
  3. Vascular Maturation: Molecules like CCL2 and CXCL8 (IL-8) are potent drivers of angiogenesis and lymphangiogenesis, directly correlating with higher tumor grades.
  4. The "Double-Edged Sword": Many chemokines exhibit dualistic roles. For instance, the CXCR3 axis can either promote or inhibit tumor growth depending on which specific splice variant is activated.

Clinical Significance: Biomarkers and Prognosis

The distinct expression patterns of chemokines in OSCC offer significant potential for clinical application. CCL2 and CXCL8 have been identified as highly promising non-invasive biomarkers, with significantly elevated levels found in the saliva of OSCC patients compared to healthy controls. Furthermore, the expression levels of certain receptors, such as CXCR4, can serve as negative prognostic indicators, helping clinicians predict the likelihood of metastasis and poor patient outcomes.

Therapeutic Implications and Future Frontiers

Current therapeutic strategies focus on disrupting the chemokine-receptor network. Clinical trials are evaluating antagonists for receptors like CCR5 and CXCR4 (e.g., Plerixafor). However, the complexity of these signaling networks—where chemokines often bind to multiple receptors—makes it difficult to predict the outcome of inhibiting a single molecule.

Future research directions include:

  • Patient Stratification: Using a patient's specific "chemokine profile" to tailor treatments.
  • Combination Therapies: Integrating chemokine antagonists with traditional chemotherapy or modern immune checkpoint inhibitors (e.g., anti-PD-1) to overcome treatment resistance.
  • Targeted Delivery Systems: Developing nanoparticles or hydrogel patches to deliver chemokine antagonists directly to the tumor, reducing systemic toxicity.

By continuing to map the intricate wiring of the chemokine system, researchers aim to develop more effective, personalized interventions that can finally improve the prognosis for patients with OSCC.

Summary updated

Abstract

Chemokines, a category of cytokines exhibiting chemotactic properties, have been thoroughly investigated as targets in cancer treatment in recent decades. In oral squamous cell carcinoma (OSCC), a prevalent and high-risk malignancy of the head and neck, chemokines interact with their specific receptors to initiate downstream signaling pathways. This signaling influences not only tumor cell proliferation, migration, invasion, and metastasis of oral cancer cells but also angiogenesis and vascular maturation. Furthermore, they modulate the tumor microenvironment (TME), which consists of diverse cellular and molecular components that collectively create a permissive niche for tumor growth, metastasis, and therapeutic resistance. This modulation impacts the recruitment and functionality of immune cells, which in turn influences tumor immune evasion and immune surveillance. Various chemokines and their receptors have distinct expression patterns in oral cancer tissues compared to normal tissues. Certain chemokines may function as prospective diagnostic markers, prognostic indicators, and therapeutic targets. In this review, we systematically summarize research advancements on chemokines in OSCC, elucidating their molecular mechanisms in tumor initiation and progression with a focus on the dualistic roles of key chemokine families (e.g., CCL2/5/20/19/21, CXCL1/8/12, CX3CL1) in regulating immune responses, tumor-stroma interactions, vascular remodeling, and chemotherapy resistance. We also recap current chemokine/receptor-targeted therapeutic strategies and discuss the limitations of existing research, including incomplete mechanistic understanding of understudied chemokine subfamilies (beyond CXC and CC subfamilies) and limited clinical translation of chemokine-based diagnostics and therapeutics. Finally, we propose future research directions: prioritizing patient stratification based on chemokine profiles, developing targeted delivery systems for chemokine antagonists, and combining these approaches with emerging therapies to overcome treatment resistance. This review underscores the critical role of chemokines in OSCC biology and their promising potential to guide the development of novel, effective therapeutic interventions.
BibTeX
@inproceedings{li2025chemokines,
  author = {Dandan Li and Shuangshuang Chen and Jiahao Ji and Zhenwu Wang and Han Zhou and Zebin Liao and Qun Tang},
  title = {{Chemokines and their receptors in oral squamous cell carcinoma: mechanisms, clinical significance, and therapeutic implications}},
  booktitle = {Frontiers in Immunology},
  year = {2025},
  doi = {10.3389/fimmu.2025.1689695},
}
Figure